niacinamide and sf 1126

niacinamide has been researched along with sf 1126 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burgoyne, AM; Durden, DL; Garlich, JR; Ikeda, S; Joshi, S; Kono, Y; Morales, GA; Sicklick, JK; Singh, AR	1

Other Studies

1 other study(ies) available for niacinamide and sf 1126

Article	Year
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Molecular cancer therapeutics, 2016, Volume: 15, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Genes, myc; Humans; Liver Neoplasms; Mice; Niacinamide; Nuclear Proteins; Oligopeptides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Transcription Initiation Site; Xenograft Model Antitumor Assays	2016

Article

Year

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Molecular cancer therapeutics, 2016, Volume: 15, Issue:11

Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Genes, myc; Humans; Liver Neoplasms; Mice; Niacinamide; Nuclear Proteins; Oligopeptides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Transcription Initiation Site; Xenograft Model Antitumor Assays

2016